|
FDA, EMA, TGA Formalize Joint Inspection Program for APIs
The U.S. Food and Drug Administration (FDA) and its EU and Australian counterparts have developed a blueprint for operating joint good manufacturing practice (GMP) inspections of active pharmaceutical ingredient (API) manufacturing facilities, the Australian Therapeutic Goods Administration (TGA) says.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Related Articles
|
Subscribe
Archives